title: [Intraoperative 125I brachytherapy combined with chemotherapy for pancreatic cancer].
abstract: OBJECTIVE
  To evaluate the efficacy, toxicity and survival of intraoperative 125I brachytherapy combined with chemotherapy for advanced pancreatic cancer.
  
  
  METHODS
  Thirty-six patients with advanced pancreatic cancer were randomized to two groups: brachy-chemotherapy group (n = 18) and control group (n = 18). For the combined group, intraoperative 125I implantation and gemcitabine, 5-Fu were given. For the control group, intratumoral injection of absolute alcohol was done.
  
  
  RESULTS
  The CR + PR rate of brachy-chemotherapy group was 38.9% with pain relief in 77.8%, while that of control group was 0 with pain relief in 22.2% (P < 0.05). Although there were some toxicity in brachy-chemotherapy group, treatment was well tolerated. The 6-, 12-month survival rates of brachy-chemotherapy group were 71.4% and 21.4% and those of control group were 38.5% and 7.7%, respectively. The median survival time was 10.6 months and 5.2 months for the two groups, between which the difference was significant (P < 0.05).
  
  
  CONCLUSIONS
  Interoperative 125I brachytherapy combined with chemotherapy for advanced pancreatic cancer can control tumor, relieve pain and improve quality of life. It is safe and effective.
authors.affiliation: Department of Surgery, Peking University First Hospital, Beijing 100034, China. wangdongmin@csco.org.cn
authors.forename: Dong-min
authors.initials: DM
authors.lastname: Wang
authors.forename: Yin-hua
authors.initials: YH
authors.lastname: Liu
authors.forename: Shi-ping
authors.initials: SP
authors.lastname: Yu
authors.forename: Xue-ning
authors.initials: XN
authors.lastname: Duan
authors.forename: Yin-mo
authors.initials: YM
authors.lastname: Yang
authors.forename: Yuan-lian
authors.initials: YL
authors.lastname: Wan
authors.forename: Gang
authors.initials: G
authors.lastname: Zhou
authors.forename: Wen-jiang
authors.initials: WJ
authors.lastname: Shen
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001918:Brachytherapy; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007432:Intraoperative Period; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D011788:Quality of Life; D015996:Survival Rate; D000093542:Gemcitabine
chemical_list: D007457:Iodine Radioisotopes; D003841:Deoxycytidine; D005472:Fluorouracil; D000093542:Gemcitabine